From Drug Target Review
The field of cell therapy has emerged as a beacon of hope, promising transformative treatments for various diseases. Diving into the intricacies of this domain, this exclusive interview explores the distinctions between two key approaches – autologous and allogeneic cell therapies. We look at the nuances of cell sourcing, preclinical challenges, and clinical possibilities, guided by the expertise of Dr Andreas Bader, a distinguished figure in the industry with a profound track record in oncology drug discovery and strategic leadership.
